NASDAQ:BCAX

Bicara Therapeutics (BCAX) Stock Price, News & Analysis

Bicara Therapeutics logo
$9.12 -0.26 (-2.77%)
Closing price 04:00 PM Eastern
Extended Trading
$9.13 +0.01 (+0.07%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Bicara Therapeutics Stock (NASDAQ:BCAX)

Advanced

Key Stats

Today's Range
$9.05
▼
$9.55
50-Day Range
$7.93
▼
$23.20
52-Week Range
$7.87
▼
$30.99
Volume
844,512 shs
Average Volume
2.30 million shs
Market Capitalization
$605.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.33
Consensus Rating
Moderate Buy

Company Overview

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses.

The company’s lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression. The candidate is being studied in clinical trials, including in head and neck cancer.

Bicara is based in the Boston area and was established in 2018. Its chief executive officer is Christopher McNulty.

AI Generated. May Contain Errors.

Bicara Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

BCAX MarketRank™: 
3.486941063855 of 5 stars

Bicara Therapeutics scored higher than 70% of companies evaluated by MarketBeat, and ranked 197th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Bicara Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.72, and is based on 2 strong buy ratings, 11 buy ratings, 3 hold ratings, and 2 sell ratings.

  • Upside Potential

    Bicara Therapeutics has a consensus price target of $30.33, representing about 232.6% upside from its current price of $9.12.

  • Amount of Analyst Coverage

    Bicara Therapeutics has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Bicara Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Bicara Therapeutics are expected to decrease in the coming year, from ($3.82) to ($4.23) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Bicara Therapeutics is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Bicara Therapeutics is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Bicara Therapeutics has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    17.29% of the float of Bicara Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Bicara Therapeutics has a short interest ratio ("days to cover") of 3.84, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Bicara Therapeutics has recently decreased by 4.24%, indicating that investor sentiment is improving.
  • Dividend Yield

    Bicara Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Bicara Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Bicara Therapeutics has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.39 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Bicara Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    13 people have searched for BCAX on MarketBeat in the last 30 days. This is an increase of 160% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Bicara Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Bicara Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $400,750.00 in company stock.

  • Percentage Held by Insiders

    13.80% of the stock of Bicara Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Bicara Therapeutics has minimal institutional ownership at this time.

  • Read more about Bicara Therapeutics' insider trading history.
Receive BCAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicara Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BCAX Stock News Headlines

Research Analysts Set Expectations for BCAX FY2026 Earnings
What is HC Wainwright's Forecast for BCAX Q1 Earnings?
The next convergence is here
In 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.tc pixel
See More Headlines

BCAX Stock Analysis - Frequently Asked Questions

Bicara Therapeutics' stock was trading at $16.83 at the beginning of the year. Since then, BCAX stock has decreased by 45.8% and is now trading at $9.12.

Bicara Therapeutics Inc. (NASDAQ:BCAX) released its quarterly earnings data on Monday, November, 9th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.82) by $0.22.
Read the conference call transcript
.

Bicara Therapeutics (BCAX) raised $298 million in an IPO on Friday, September 13th 2024. The company issued 17,500,000 shares at a price of $16.00-$18.00 per share.

Bicara Therapeutics' top institutional shareholders include State Street Corp (3.11%), Bellevue Group AG (1.09%), Nan Fung Trinity HK Ltd. (0.65%) and Goldman Sachs Group Inc. (0.61%). Insiders that own company stock include Ra Capital Management, LP, Claire Mazumdar, Ryan Cohlhepp, Ivan Hyep and David Raben.
View institutional ownership trends
.

Shares of BCAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
11/09/2026
Today
11/19/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:BCAX
Previous Symbol
NASDAQ:BCAX
CIK
2023658
Fax
N/A
Employees
103
Year Founded
2020

Price Target and Rating

High Price Target
$43.00
Low Price Target
$8.00
Potential Upside/Downside
+232.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.72
Research Coverage
18 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$137.95 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-49.13%
Return on Assets
-45.01%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.81
Quick Ratio
8.81

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.17 per share
Price / Book
1.48

Miscellaneous

Outstanding Shares
66,390,000
Free Float
57,226,000
Market Cap
$605.48 million
Optionable
Optionable
Beta
-0.33

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:BCAX) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners